Subscribe to our Newsletters !!
Eliminating sticker residue is a small yet frustra
WIGGENS Shaking Incubators combin
The Nobel Prize in Physiology or Medicine awarded
Giesen, Germany. 26 January 2026 - At Interpack 20
Alembic Pharmaceuticals Limited (Alembic) today an
Tofu has been a favorite food for vegetarians and
Dear Readers, Welcome to the latest issue of Micr
For almost 20 years, custom medicine’s potential for success has been driven by the ability to potentially identify molecular signatures for a disease’s etiology instead of population-based markers. Currently, the molecular signatures of diseases have the potential to positively integrate a multitude of technological, biological, and computational advancements, and transform the field of genomics from the research phase to practical, real-world clinical applications in oncology, neonatal medicine, rare diseases, and pharmacogenomics.
Advances have enabled the field to develop an ecosystem with next-generation sequencing (NGS), functional genomics, pangenomics, genome engineering, and AI-based analytical tools. These advancements are changing how healthcare operates by shifting the focus toward predictive, preventive, and personalized healthcare.
The most impactful development in genomics has been the addition of whole genome sequencing (WGS) to standard diagnostics. Pediatric and emergency medicine have been revolutionized by the ability to make a genetic diagnosis in as little as a few hours using ultra-rapid sequencing. In The New England Journal of Medicine, distributed cloud nanopore technologies enabled rapid diagnosis of genetic conditions in under 8 hours, which in turn, facilitated life-saving treatments to critically ill patients in both pediatric and adult ICUs. The GUARDIAN initiative in New York City screened 100,000 newborns for genes associated with conditions warranting immediate clinical intervention. GUARDIAN successfully identified an actionable variant in approximately 3.7% of screened babies that would have been missed by the conventional/published standard newborn screening panels.
The UK and other major countries have decided to implement WGS for all newborns. This demonstrates a paradigm shift in that precision medicine begins with a newborn, not simply a diagnosis of a disease.
In cancer care, tumor-specific genomic analysis is considered the foundation of personalized medicine. Comprehensive genomic profiling (CGP) is used to determine the best treatment options and prognosis, as well as to assess and manage minimal residual disease (MRD) status. A significant body of evidence supports the clinical benefit of CGP directed treatment.
The use of liquid biopsy and circulating tumor DNA (ctDNA) have further enhanced the utility of CGP in cancer care, allowing for the detection of resistance mutations and the monitoring of disease in a non-invasive manner. These technologies have enabled a shift in cancer care from a reactive to an anticipatory paradigm.
Over 300 million people suffer from rare genetic disorders worldwide, many enduring years of testing with no conclusive results. Journeying through the world of genomics offers hope in alleviating this suffering.
The latest reports claim that traditional methods of blending genomics and neurology fall short versus whole exome and genome sequencing which, in some studies, have conveniently provided 60% of the case study subjects with confirmed neurological diagnoses. That is, in fact a case study of neurology; while precision medicine has illustrated that rapid molecular diagnoses (supporting those practitioners to potentially intervene sooner in order to facilitate medical and genetic testing in patients and their relatives, as well as facilitate more effective and efficient clinical decisions).
The initiatives and goals of the world’s population genome and human pangenome have demonstrated the ability to contribute to the equitability of global variant interpretation/diagnostics.
Clinical prescriptions have seen a revolution through the advent of genomic data. Pharmacogenomic testing anticipates and reveals the increased probability of adverse drug reactions and treatment failures.
Evidence illustrates that genomics impacts the dosing of major drugs such as chemotherapy and antidepressants by determining the function of specific enzymes and how different drugs metabolize due to genetic variants. With increased utilization in daily practice, it is expected that pharmacogenomics will become one of the routine features in the electronic health records and clinical decision support systems.
CRISPR technology is advancing from a lab-based and research-based tool toward a clinical and therapeutic application. By 2025, CRISPR approaches will have clinical-grade therapeutic pipeline advancements and regulatory approvals expected.
Potential areas of application include certain inherited blood disorders, specific types of metabolic disorders, and cancer. Innovations in compact genome editors, base editing, and others will broaden available treatment options. Improving validation, safety, and responsible governance frameworks for clinical use will support the safe clinical use of these advancing technologies.
Genome editing is an active developing therapeutic method.
The health and disease continuum cannot be explained solely by genomics. Precision medicine, in conjunction with AI, has begun to utilize multiomics—transcriptomics, proteomics, epigenomics (offers a means to address the regulation of gene expression), metabolomics, and microbiomics—to develop a comprehensive understanding of biological systems.
The most recent literature acknowledges the integration of multiomics and sophisticated AI as a breakthrough for deriving mechanistic understanding, modeling pathways of disease, and guiding personalized interventions. AI, in particular, is emerging as a primary means of sophisticated decision-making in precision medicine when integrated with genomics, multimodal imaging, electronic health record data, and other social determinants of health.
In pediatric research, the value of multiomics is most apparent in the identification of genotype phenotype correlations, the subclassification of disease, and the enhancement of diagnostic accuracy.
With new capabilities, new responsibilities emerge. In order to implement precision medicine, we must develop:
The global pangenome and inclusive sequencing initiatives’ global partnerships are opening new horizons to address the underrepresentation.
The analytics and sequencing of precision medicine are dependent on numerous advanced technologies. However, the cornerstone of this discipline is the sample quality, workflow reproducibility, and laboratory infrastructure dependability. Thermo Fisher Scientific supports the precision medicine driven genomics ecosystem by providing available solutions throughout the genomics value chain.
High‑quality genomics starts with high‑quality sample handling:
During extraction and library prep, yields of DNA/RNA are preserved in low binding tubes. For accurate variant detection, the PCR/qPCR plates and optical seals help reduce evaporation and help retain heat.
Creating contamination free pipetting while providing precision molded, sterile, and disposable tips for genome sequencing, CRISPR workflows, and library prep for NGS.
Guaranteeing the integrity of samples from the first collection all the way through downstream molecular workflows.
These plastics assist in retaining purity.
We provide robust equipment that maintains the controlled environments required for sequencing and precision‑medicine workflows:
Allowing for precise and reproducible handling of liquids during library preparation, PCR setup, and enzymatic assays.
Enabling controlled separations for blood, tissue, and cellular samples that are critical for NGS library preparation and QC.
Facilitating workflows for cell-based genomics, CRISPR editing, and primary cells in contamination-free environments.
−20 °C, −80 °C, and cryogenic systems preserve DNA, RNA, cell models, and genomic reference materials through long‑term storage.
Across the workflow, these technologies promote reproducibility, robustness, and continuity—key to scaling genomic medicine.
With the evolution of genomics into standard practice in the health care industry, the arrival of precision medicine is on the horizon. Sensory technology, large-scale analysis of newborn screening, quick analysis of patients using artificial intelligence, and genome editing technologies are impacting how we diagnose and treat patients as never before. The patient-oriented genomics is advancing rapidly, and we are not predicting the future of medicine; we are creating it.
